Albert Selva O'Callaghan I've been a doctor for over 30 years now and I work at the Vall d'Hebron University Hospital. Institutions of which they are part Main researcher Systemic Diseases Vall Hebron Institut de Recerca Internal Medicine General Hospital Email Albert Selva O'Callaghan Email Institutions of which they are part Main researcher Systemic Diseases Vall Hebron Institut de Recerca Internal Medicine General Hospital I've been a doctor for over 30 years now and I work at the Vall d'Hebron University Hospital.
Was born in Barcelona on May 1st, 1959. He obtained his medical degree at the University Autonomous of Barcelona in 1982, and so he did also the Doctoral Thesis at the same University in 1992. Since 2010 he is Associated Professor of Medicine, since june 2021 Full Professor. He attended to the internal resident program (MIR) at the Internal Medicine Department at Vall d’Hebron General Hospital in Barcelona from 1986 to 1990, and currently is working as a Senior Consultant and as Head at the Systemic Autoimmune Diseases Unit at the same hospital. He has been focused to the study of idiopathic inflammatory myopathy for more than 25 years and has published several relevant articles and book chapters on the field. Taking care of the patients, teaching at the University and doing research are the three main activities in regard to myositis patients he is committed to.
Research lines Cancer and myositis. Relevance of the anti-p155 antibodies and importance of the screening for cancer by Positron Emission Tomography and Computed Tomography (PET/CT). Anti-p155 antibodies seem to be useful for the diagnosis of paraneoplastic myopathies. We have studied their prevalence and their diagnosis value in a cohort of 137 patients with inflammatory myopathies and we have observed that they have a high negative predictive value. On the other hand, the screening by PET/TC does not contribute much to the conventional screening of cancer in these patients. IP: Albert Selva O'Callaghan MYOGEN study. Genome Wide Association study in myositis. We are currently enrolled in this worldwide study to detect global genetic alterations in patients with myositis. Twenty centres from Europe and United States participate in this study. We contribute to add the genetic information of the patients from our population. Professor Frederick W. Miller (Bethesda, USA) and Dr. Ingrid Lundberg (Stockholm, Sweden) lead the project. IP: Albert Selva O'Callaghan International Classification Criteria Project. This is a multicentric study aimed at defining new diagnosis criteria for muscular inflammatory diseases. Although criteria given by Bohan and Peter are still used in clinical practice, some inflammatory diseases such as inclusion body myositis are not included. The hytopathological classification performed by Dalakas includes the latter entity but it does not take into account neither the paraneoplastic myositis nor those associated to systemic diseases. IP: Albert Selva O'Callaghan Lung involvement in inflammatory myopathies. With this study we want to study the natural history of this syndrome mediated by anti-synthetase antibodies, the characterization of new antibodies that may be used as markers for lung involvement, as well as we aim at understanding better the etiopathogenicity and the treatment of this organic illness in patients with myositis. IP: Albert Selva O'Callaghan Pagination Current page 1 Page 2 Next page › Last page » Projects Ajuts Grups de Recerca (SGR) 2022 IP: Jaume Alijotas Reig Collaborators: Moisés Labrador Horrillo, Carmen Pilar Simeón i Aznar, Anna Sala Cunill, Roser Solans Laque, Segundo Bujan Rivas, Mar Guilarte Clavero, Vicenç Fonollosa Pla, Fernando Martínez Valle, Victòria Cardona Dahl, Francesc Miro Mur, Alfredo Guillen Del Castillo, Albert Selva O'Callaghan, José Pardos Gea, Laura Donaire Lancharro, Ariadna Anunciacion Llunell Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00048 Duration: 01/01/2022 - 30/06/2025 Caracterización de las células patogénicas del músculo y piel de pacientes con Dermatomiositis y Síndrome Antisintetasa y estudio de aplicabilidad traslacional. IP: Ernesto Trallero Araguas Collaborators: Albert Selva O'Callaghan, Raul Tortosa Mendez, Albert Gil Vila, Gloria Aparicio Español, Adria Aterido Ballonga, Hugo Fernando Avalos Bogado Funding agency: Instituto de Salud Carlos III Funding: 135520 Reference: PI22/00708 Duration: 01/01/2023 - 31/12/2025 COVID-19, PERFIL INMUNOLÓGICO DE RIESGO IP: - Collaborators: Manuel Hernández González, Mónica Martínez Gallo, Moisés Labrador Horrillo, Gema Codina Grau, Albert Blanco Grau, Andres Antón Pagarolas, Antonio Álvarez Fernandez, Nuria Fernández Hidalgo, Roser Ferrer Costa, Esteve Ribera Pascuet, Juan Carlos Ruiz Rodriguez, Jaume Ferrer Sancho, Anna Suy Franch, Pere Soler Palacín, Albert Selva O'Callaghan, Tomàs Pumarola Suñé, Isabel Ruiz Camps, Daniel Alvarez De la Sierra, Andrea Martín Nalda, Eva Polverino, Romina Dieli Crimi, Romina Dieli Crimi Funding agency: Instituto de Salud Carlos III Funding: 229000 Reference: COV20/00416 Duration: 08/05/2020 - 08/11/2021 Inflitrado tumoral linfocitario (TIL) y dematomiositis asociada a cáncer. IP: Albert Selva O'Callaghan Collaborators: Ernesto Trallero Araguas, Maria Eugenia Semidey Raven Funding agency: Instituto de Salud Carlos III Funding: 129470 Reference: PI18/01609 Duration: 01/01/2019 - 30/06/2023 Pagination Current page 1 Page 2 Page 3 Next page › Last page »
